UPDATE
1-Allergy Therapeutics says study fails to
find hay
fever therapy dose range
June 27 (Reuters) – Drug developer Allergy
Therapeutics Plc
said a
study on suitable doses of its
therapy to treat
grass allergic rhinitis, or hay fever, did **t
find a
recommended
dose for a late-stage trial.
